Suggestions
Bhavesh Patel, PhD
Principal in Life Sciences Strategy Consulting
Dr. Bhavesh Patel is a seasoned strategy consultant in the field of Life Sciences with a strong track record of global engagements focused on key areas like pricing, market access, commercial strategy, and evidence generation. With a background in Chemistry, holding a PhD and a Master's degree from Imperial College London, Dr. Patel has diverse experience across pharmaceutical, biotech, and medtech sectors. He is currently a key member of the strategy team at CRA where he provides independent and balanced recommendations to industry giants. Dr. Patel's passion lies in oncology and rare diseases, where he leads internal initiatives while also exploring interests in various therapeutic areas like cardiovascular diseases, nephrology, immunology, and medical devices. His rich professional history includes roles at renowned organizations like Charles River Associates, QuintilesIMS, and notable stints in academia and industry placements.
Highlights
The much needed #innovation is coming, across #raredisease, #oncology, and beyond: "...the #ATMP ecosystem is still developing, and there is much more to do to ensure that #patients [...] #access the number and variety of ATMPs expected to become available in the coming years", and there is still work to be done to ensure #healthcaresystems can manage/fund these potentially life-changing therapies.
Read this forward-looking report from #ABPI, written by my colleagues at #CRA, focusing on understanding how the challenges of providing patients with access to ATMPs will evolve over the next five years, and learning from international experiences of improving access to ATMPs
Lots going on in the #radiopharmaceuticals and #targetedradiotherapy field at the moment! From successful #acquisitions to challenges with #supply constraints impacting clinical trial enrollment to advances in #diagnostics to #actinium-225 based therapies showing more potential as a serious contender to some of the established #lutetium-117 based therapies. Looking forward to seeing how this space evolves in the coming years and the potential impact in #oncology and beyond!
